5,162 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Point72 Hong Kong Ltd

Point72 Hong Kong Ltd bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 5,162 shares of the company’s stock, valued at approximately $84,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TEVA. Janney Montgomery Scott LLC increased its position in Teva Pharmaceutical Industries by 13.6% during the first quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock worth $19,366,000 after acquiring an additional 164,614 shares during the period. QRG Capital Management Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 53.7% during the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after purchasing an additional 50,247 shares during the period. Capital Wealth Planning LLC bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $2,169,000. Public Employees Retirement Association of Colorado grew its position in Teva Pharmaceutical Industries by 1,382.8% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 255,826 shares of the company’s stock worth $2,671,000 after buying an additional 238,573 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in Teva Pharmaceutical Industries by 12.0% during the first quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock valued at $8,613,000 after acquiring an additional 65,529 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on TEVA. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday, September 23rd. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Finally, Jefferies Financial Group lifted their price objective on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.89.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $17.46 on Friday. Teva Pharmaceutical Industries Limited has a 52 week low of $8.06 and a 52 week high of $19.08. The stock has a market capitalization of $19.78 billion, a PE ratio of -42.59, a PEG ratio of 1.23 and a beta of 0.88. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The stock’s fifty day moving average is $17.75 and its 200-day moving average is $16.18.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.